The blockbuster drug semaglutide, better known as Ozempic for diabetes and Wegovy for obesity, could also help people cut ...

Apple Podcasts, Spotify, or wherever you find your favorite podcasts.This is The Takeaway from today's Morning Brief, which you can sign up to receive in your inbox every morning along with: The chart ...

Insurers also ask the Trump administration, which is engaged in a sweeping campaign to eradicate anything related to ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

DeepSeek’s recent claim that it can make artificial intelligence less power-hungry is just the latest reason the energy ...

Robert F. Kennedy Jr. told the Senate Finance Committee that he is not anti-vaccine during his confirmation hearing for ...

High Tide Inc reports fourth-quarter financial results after the market close on Wednesday. Here's a look at the highlights ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk's Ozempic to lower the risk of kidney failure and disease progression. According to a statement made by the Danish ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...